Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Lilly expand strategic partnership first established in 2023 Investment will significantly increase U.S. production of Lilly’s...
BLOG
Read on
Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities
BLUE ASH, Ohio, June 18, 2026 – Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today...
Key Steps in the Vaccine Scale-up Journey
In this roundtable discussion, experts from Resilience will discuss key steps in getting vaccines from development to the global market. You’ll hear...
Boston, MA: Process & Analytical Development and Manufacturing Facility
The launch of our Process & Analytical Development and Manufacturing Facility marks a strategic resurgence in the Boston area, as we consolidate and...
On-Demand Webinar: Outsourced Pharma Capacity Update 2024 - Large Molecules
Are you an innovative company looking for a dependable CDMO partner for your large molecule projects? You have come to the right place.
Scale Your Vaccine Development with Path-to-PAD
The COVID-19 pandemic highlighted the urgent need for a quick, efficient, and scalable vaccine production process. Resilience's Vaccine Path-To-PAD...
Successful Development and Manufacturing of Vaccines Containing Aluminum Adjuvants
When added to vaccines, adjuvants such as aluminum salts can provide various benefits to drug products. Understanding the challenges associated with...
The Challenges and Solutions for Viral Products
The proliferation of recombinant protein therapies has driven the need for new capacity in the biotherapeutic manufacturing space. Monoclonal...
